Dr. Saphire will become La Jolla Institute’s fifth president when she formally begins her term on September 1, 2021
Leinco Technologies, Inc., and La Jolla Institute for Immunology announce license agreement to develop novel COVID-19 diagnostic tools
In addition to developing the antibodies for use in diagnostic applications based on N protein-specific antibodies, Leinco will make these antibodies commercially available as part of their extensive catalogue of research tools.
To speed inoculations, the U.S. plans to release all available vaccine doses and open access to anyone over 65. Others suggest straying from recommended doses or intentionally delaying boosters. The best way forward remains uncertain.
San Diego scientists and trial participants are cautiously optimistic after early reports that Pfizer’s COVID-19 vaccine is highly effective
LA JOLLA, CA—Ever since SARS-CoV-2 first appeared, researchers have been trying to understand whether sometimes the immune system does more